Gut microbiota and inflammation in chronic kidney disease patients

Clinical Kidney Journal

Volumn 8, Issue 3, 2015, Pages 332-334

  Mafra, Denise ^a   Fouque, Denis ^b  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Chronic kidney disease; Gut microbiota; Inflammation

Indexed keywords

BACTERIAL DNA; UREMIC TOXIN;

ARTICLE; CHRONIC KIDNEY DISEASE; DENATURING GRADIENT GEL ELECTROPHORESIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTESTINE FLORA; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84942236296     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfv026     Document Type: Article

References (22)

1. Mafra D, Lobo JC, Barros AF et al. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. FutureMicrobiol 2014; 9: 399-410
2. Le Chatelier E, Nielsen T, Qin J et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013; 500: 540-549
3. Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens 2012; 21: 587-592
4. Hida M, Aiba Y, Sawamura S et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996; 74: 349-355
5. Wang IK, Lai HC, Yu CJ et al. Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients. Appl Environ Microbiol 2012; 78: 1107-1112
6. Vaziri ND, Wong J, Pahl M et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013; 83: 308-315
7. Wong J, Piceno YM, DeSantis TZ et al. Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 2014; 39: 230-237
8. Barros AF, Borges NA, Ferreira DC et al. Is there interaction between gut microbial profile and cardiovascular risk in chronic kidney disease patients? Future Microbiol 2015; 10: 517-526
9. Shi K, Wang F, Jiang H et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci 2014; 59: 2109-2117
10. Vanholder R, Glorieux G. The intestine and the kidneys: a bad marriage can be hazardous. Clin Kidney J 2015; 8: 168-179
11. Liabeuf S, Barreto DV, Barreto FC et al. European uraemic toxin work group (EUTox): free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1183-1191
12. Lin CJ, Liu HL, Pan CF et al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch Med Res 2012; 43: 451-456
13. Niwa T, Shimizu H. Indoxyl sulfate induces nephrovascular senescence. J Ren Nutr 2012; 22: 102-106
14. Soulage CO, Koppe L, Fouque D. Protein-bound uremic toxins ... new targets to prevent insulin resistance and dysmetabolism in patients with chronic kidney disease. J Ren Nutr 2013; 13: 128-133
15. Muccioli GG, Naslain D, Bäckhed F et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 2010; 6: 392
16. Mafra D, Barros AF, Fouque D. Dietary protein metabolism by gut microbiota and its consequences for chronic kidney disease patients. Future Microbiol 2013; 8: 1317-1323
17. Ranganathan N, Ranganathan P, Friedman EA et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 2010; 27: 634-647
18. Hyun HS, Paik KH, Cho HY. p-Cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis. Korean J Pediatr 2013; 56: 159-164
19. Wang IK, Wu YY, Yang YF et al. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Benef Microbes 2015; 21: 1-8
20. Hempel S, Newberry S, Ruelaz A et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep) 2011; 200: 1-645
21. Meijers BK, De Preter V, Verbeke K et al. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2010; 25: 219-224
22. Vaziri ND, Liu SM, Lau WL et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One 2014; 9: e114881